|
|
Profile
|
Delegates :
Hiroaki Goto |
|
Incorporated :
February , 2016 |
Paid in Capital :
96 Million yen |
Employees :
8 人 |
Address :
6F Hankyu Senri Chuo Building, 1-4-1 Shinsenri Higashimachi, Toyonaka, Osaka OSAKA
〒560-0082
|
TEL/FAX :
06-6836-5373 / |
URL：
https://pain-ml.com/en/ |
Attachment :
|
Mission/Background :
PaMeLa, a venture from Osaka University, develops systems to "visualize" pain using big data analysis and AI. Their goal is to standardize pain evaluation metrics and reduce patient suffering. They focus on software and hardware development, offering services to medical institutions to improve care. Actively involved in medical exhibitions, the company aims to expand internationally |
|
Technology & Business
|
PaMeLa is developing an objective pain assessment device that quantifies pain on a 0-100 scale in real-time by combining EEG data, less influenced by subjectivity, with AI. This allows doctors to assess patients' pain objectively, improving the convenience and efficiency of pain diagnosis.
Currently, pain evaluation relies on self-reporting, which can result in inaccurate diagnoses, inappropriate treatments, decreased QoL, prolonged hospital stays, and higher medical costs. Busy medical settings also limit time for pain consultations, leaving patients unheard. PaMeLa's device addresses these issues by enabling real-time pain measurements via simple steps like attaching electrodes to the forehead and using an app.
The company completed exploratory clinical trials in 2021 and began confirmatory trials in 2024, moving toward regulatory approval.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
PMS−２
|
Phase2/3
|
Objective pain assessment device
|
Completion of clinical trial, Regulatory application
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
Initiation of clinical trial with two national university hospitals
|
|
Alliance strategy
|
We are seeking business partners to commercialize our products and technology. While we are pursuing business targeting medical institutions as our intended customers, we believe our technology also holds great potential in pharmaceutical development for pharmaceutical companies.
|
|
|